Celera has entered into a research collaboration with Merck to develop biomarker and pharmacogenomic tests for cancer patients. Under the terms of the agreement, Celera will evaluate certain gene expression profiles identified by Merck with the goal of developing diagnostic predictors for use in Merck's clinical trials, and to potentially form the basis for commercial diagnostic tests for oncology therapies.

Celera will receive an undisclosed payment for this collaboration and is eligible to receive an additional payment if Merck transfers a Celera validated gene expression assay to a clinical reference lab upon completion.

"This collaboration with Merck is a strong validation of Celera's diagnostic expertise in targeted medicine and our development capabilities," said Thomas White, Ph.D., chief scientific officer at Celera. "The potential outcomes from this collaboration could lead to the development of tests that may improve individualized therapy for the treatment of cancer."

News from our sister sites